Navigation Links
Penn research using frog embryos leads to new understanding of cardiac development
Date:4/22/2011

PHILADELPHIA--During embryonic development, cells migrate to their eventual location in the adult body plan and begin to differentiate into specific cell types. Thanks to new research at the University of Pennsylvania, there is new insight into how these processes regulate tissues formation in the heart.

A developmental biologist at Penn's School of Veterinary Medicine, Jean-Pierre Saint-Jeannet, along with a colleague, Young-Hoon Lee of South Korea's Chonbuk National University, has mapped the embryonic region that becomes the part of the heart that separates the outgoing blood in Xenopus, a genus of frog.

Xenopus is a commonly used model organism for developmental studies, and is a particularly interesting for this kind of research because amphibians have a single ventricle and the outflow tract septum is incomplete.

In higher vertebrates, chickens and mice, the cardiac neural crest provides the needed separation for both circulations at the level of the outflow tract, remodeling one vessel into two. In fish, where there is no separation at all between the two circulations, the cardiac neural crest contributes to all regions of the heart.

"In the frog, we were expecting to find something that was in between fish and higher vertebrates, but that's not the case at all," said Saint-Jeannet. "It turns out that cardiac neural crest cells do not contribute to the outflow tract septum, they stop their migration before entering the outflow tract. The blood separation comes from an entirely different part of the embryo, known as the 'second heart field.'"

"As compared to other models the migration of the cardiac neural crest in amphibians has been dramatically changed through evolution," he said.

Saint-Jeannet's research will be published in the May 15 edition of the journal Development.

To determine where the neural crest cells migrated during development, the researchers labeled the embryonic cells with a fluorescent dye, then followed the path those marked cells took under a microscope. "We label the cardiac neural crest cells in one embryo and then graft them onto an embryo that is unlabeled. We let the embryo develop normally and look where those cells end up in the developing heart," said Saint-Jeannet.

Knowing these paths, and the biological signals that govern them, could have implications for human health.

"There are a number of pathologies in humans that have been associated with abnormal deployment of the cardiac neural crest, such as DiGeorge Syndrome," said Saint-Jeannet. "Among other developmental problems, these patients have an incomplete blood separation at the level of the outflow tract, because the cardiac neural crest does not migrate and differentiate at the proper location."

DiGeorge syndrome is present in about 1 in 4,000 live births, and often requires cardiac surgery to correct.

"Xenopus could be a great model to study the signals that cause those cells to migrate into the outflow tract of the heart,' said Saint-Jeannet. "If you can understand the signals that prevent or promote the colonization of this tissue, you can understand the pathology of something like DiGeorge syndrome and perhaps figure out what kind of molecule we can introduce there to force those cells to migrate further down."


'/>"/>

Contact: Evan Lerner
elerner@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert  

Related medicine news :

1. 17th Annual International Sustainable Development Research Conference
2. Empowered Workers More Productive, Research Shows
3. DFG establishes 4 new research units
4. Happiest places have highest suicide rates says new research
5. Couch-Potato Kids: It Shows in Their Eyes, Researchers Say
6. Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find
7. Rice wins $1.2 million for heart-valve tissue research
8. Women Taking Calcium Supplements May Risk Heart Health, Researchers Say
9. WSU files for patent on researchers vaccine technology for chlamydia
10. Outstanding quality of science at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) underlines conference goal of translating HIV research into practice
11. NYU Langone Medical Center awarded $4.5 million for breast cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn research using frog embryos leads to new understanding of cardiac development 
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: